Morbidity after surgical management of cervical cancer in low and middle income countries: A systematic review and meta-analysis by Allanson, Emma R et al.
The University of Notre Dame Australia 
ResearchOnline@ND 
Health Sciences Papers and Journal Articles School of Health Sciences 
2019 
Morbidity after surgical management of cervical cancer in low and middle 
income countries: A systematic review and meta-analysis 
Emma R. Allanson 
Aime Powell 
The University of Notre Dame Australia, aime.powell@nd.edu.au 
Max Bulsara 
The University of Notre Dame Australia, max.bulsara@nd.edu.au 
Hong Lim Lee 
Lynette Denny 
See next page for additional authors 
Follow this and additional works at: https://researchonline.nd.edu.au/health_article 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
 
This article was originally published as: 
Allanson, E. R., Powell, A., Bulsara, M., Lee, H. L., Denny, L., Leung, Y., & Cohen, P. (2019). Morbidity after surgical management of 
cervical cancer in low and middle income countries: A systematic review and meta-analysis. PLoS ONE, 14 (7). 
Original article available here: 
https://doi.org/10.1371/journal.pone.0217775 
This article is posted on ResearchOnline@ND at 
https://researchonline.nd.edu.au/health_article/278. For more 
information, please contact researchonline@nd.edu.au. 
Authors 
Emma R. Allanson, Aime Powell, Max Bulsara, Hong Lim Lee, Lynette Denny, Yee Leung, and Paul Cohen 
This article is available at ResearchOnline@ND: https://researchonline.nd.edu.au/health_article/278 
This article has been published in PLoS ONE. 
Published by the Public Library of Science. 
Available at: https://doi.org/10.1371/journal.pone.0217775 
This is an Open Access article distributed in accordance with the Creative Commons Attribution 4.0 
International license (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original author and source are credited. 
See: https://creativecommons.org/licenses/by/4.0/    
Allanson, E.R., Powell, A., Bulsara, M., Lee, H.L., Denny, L., Leung, Y., and Cohen, P. (2019) 
Morbidity after surgical management of cervical cancer in low and middle income countries: A 
systematic review and meta-analysis. PLoS ONE, 14(7). doi: 10.1371/journal.pone.0217775 
RESEARCH ARTICLE
Morbidity after surgical management of
cervical cancer in low and middle income
countries: A systematic review and meta-
analysis
Emma R. AllansonID1*, Aime Powell2, Max Bulsara2, Hong Lim Lee3, Lynette Denny4,5,
Yee Leung1, Paul CohenID1,6
1 Division of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Western
Australia, Crawley, WA, Australia, 2 Institute for Health Research, University of Notre Dame Australia,
Fremantle, WA, Australia, 3 Obstetrics and Gynaecology, Joondalup Health Campus, Joondalup, WA,
Australia, 4 Department Obstetrics and Gynaecology, University of Cape Town, Cape Town, South Africa,
5 South African Medical Research Council Gynaecological Cancer Research Centre, Cape Town, South
Africa, 6 Department of Gynaecological Oncology, Bendat Family Comprehensive Cancer Centre, St John of
God, Subiaco, WA, Australia
* Emma.allanson@gmail.com
Abstract
Objective
To investigate morbidity for patients after the primary surgical management of cervical can-
cer in low and middle-income countries (LMIC).
Methods
The Pubmed, Cochrane, the Cochrane Central Register of Controlled Trials, Embase,
LILACS and CINAHL were searched for published studies from 1st Jan 2000 to 30th June
2017 reporting outcomes of surgical management of cervical cancer in LMIC. Random-
effects meta-analytical models were used to calculate pooled estimates of surgical compli-
cations including blood transfusions, ureteric, bladder, bowel, vascular and nerve injury, fis-
tulae and thromboembolic events. Secondary outcomes included five-year progression free
(PFS) and overall survival (OS).
Findings
Data were available for 46 studies, including 10,847 patients from 11 middle income coun-
tries. Pooled estimates were: blood transfusion 29% (95%CI 0.19–0.41, P = 0.00, I2 =
97.81), nerve injury 1% (95%CI 0.00–0.03, I2 77.80, P = 0.00), bowel injury, 0.5% (95%CI
0.01–0.01, I2 = 0.00, P = 0.77), bladder injury 1% (95%CI 0.01–0.02, P = 0.10, I2 = 32.2),
ureteric injury 1% (95%CI 0.01–0.01, I2 0.00, P = 0.64), vascular injury 2% (95% CI 0.01–
0.03, I2 60.22, P = 0.00), fistula 2% (95%CI 0.01–0.03, I2 = 77.32, P = 0.00,), pulmonary
embolism 0.4% (95%CI 0.00–0.01, I2 26.69, P = 0.25), and infection 8% (95%CI 0.04–0.12,
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I2 95.72, P = 0.00). 5-year PFS was 83% for laparotomy, 84% for laparoscopy and OS was
85% for laparotomy cases and 80% for laparoscopy.
Conclusion
This is the first systematic review and meta-analysis of surgical morbidity in cervical cancer
in LMIC, which highlights the limitations of the current data and provides a benchmark for
future health services research and policy implementation.
Introduction
Cervical cancer is the third most common malignancy in women worldwide and performs
poorly in all objective measurements of outcomes in less developed countries[1]. The disease
is a notable example of an extreme global health disparity with almost all cervical cancers, and
the deaths caused by them, occurring in low and middle-income countries (LMIC)[2]. Con-
tributors to this inequity are complex and multifaceted and include insufficient access to HPV
vaccines and screening, and lack of trained health care professionals, radiation services and
infrastructure, that prohibit reductions in cervical cancer incidence and mortality within these
countries [3].
Opportunities to prevent and control cervical cancer arise from the human Papillomavirus
(HPV) vaccine and adopting an organised approach to cervical screening. Whilst there have
been global efforts towards this, for the half a million women with cervical cancer in LMIC,
access to appropriate surgical, radiotherapy, and chemotherapy treatments are critical to
reducing the burden of disease in LMIC and should remain a focus of global healthcare [4–7].
Surgical care should be a fundamental component of all health systems regardless of devel-
opment level. This is particularly relevant in LMIC, where surgeons may be the sole physician
involved in delivery of cancer care[3]. The delivery of high-quality surgical services that treat
cervical cancer will prevent deaths, limit disability and suffering and promote economic
growth (15). Research investigating surgical outcomes is critical to improve patient health out-
comes. Practitioner adherence to protocols should be tracked and adverse events openly
reviewed (15). Currently patients in LMIC are over-represented in reports of global rates of
adverse surgical outcomes[8], with women’s cancers having been long neglected in these set-
tings[9]. Allowing for variations in reporting, overall complication rates for radical hysterec-
tomy are, often from single centres[10], reported at up to 37% [11, 12], and rates of individual
complications, e.g. voiding dysfunction, are reported at up to 42%[13, 14]. However, these
reports largely come from high-income countries.
Data regarding cervical cancer surgical outcomes in LMIC are lacking and a baseline mea-
sure is necessary in order to advocate for ongoing quality care in these countries. Therefore,
this systematic review and meta-analysis aims to report the morbidity of cervical cancer sur-
gery in LMIC and provides a benchmark for future research initiatives.
Materials and methods
This systematic review and meta-analysis was performed in accordance with the Preferred
Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines [15]. We
searched Pubmed, Cochrane, the Cochrane Central Register of Controlled Trials, Embase,
LILACS, and CINAHL to identify all relevant articles published January 1, 2000, to June 30,
Cervical cancer surgery in LMIC
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2017, without language restriction. The year 2000 was chosen as the limit of the search for
both pragmatic reasons and in order that the findings were reflective of current practice.
We applied a search strategy combining relevant terms, including: Uterine Cervical Neo-
plasms/surgery AND ((Hysterectomy/adverse effects�) OR (Laparoscopy/adverse effects) OR
(Postoperative Complications�) OR (Operative Time) OR (Perioperative Period�) OR (Blood
Loss, Surgical) OR (Intraoperative Complications) OR (Ureter) OR (Cystotomy) OR (Intes-
tines/surgery) OR (Urinary Bladder, Neurogenic) OR (Lymphocele) OR (Fistula)) OR
(Hystere� OR Laparo� OR Complication� OR Operati� OR Blood OR Morbidity OR Bowel
injury OR Pelvic abscess OR Vascular injury OR Lymph�)). The full search strategy can be
found in S1 Table. Reference lists from full text articles identified following the title and abstract
screen were hand searched for any additional references relevant to the review question.
Inclusion and exclusion criteria
Included participants were women in a LMIC [16], with a diagnosis of cervical cancer under-
going surgical intervention. The exception to this was for studies from Taiwan, for which the
data (for most indicators) is added to high-income country aggregates [17]. Surgical manage-
ment was defined as a simple or radical hysterectomy (+/- pelvic lymphadenectomy or pelvic
lymph node dissection). All studies were required to have a minimum of 20 cervical cancer
patients (at a minimum rate of 5 patients per year included, to avoid overestimation of
complications, such as from small case series) and report on at least two surgical complica-
tions. Studies were excluded if there were no data available on the individual surgical
complications.
Two investigators independently screened the titles and abstracts of articles retrieved from
the literature search, and the full texts of potentially eligible articles were obtained and further
assessed for final inclusion (Refer to Fig 1). Disagreements were resolved through consensus.
Outcome measures
The primary measure was to evaluate the reported prevalence of surgical morbidity for cervical
cancer patients treated with surgery in LMIC. Secondary outcome measures included progres-
sion free survival (PFS) (the time from surgery to the first relapse, progression of existing dis-
ease or the last contact date) and OS (the interval from surgery to death (from any cause).
Classification of surgical outcomes
Complications were extracted as reported by the authors of each study (S1 File). Four authors
(EA, AP, PC, YL) reviewed these in a collaborative session and agreed on the grouping of com-
plications for analysis. Some complications were not considered surgical morbidity (for exam-
ple, “IUD withdrawal difficulty”) and so were excluded from any further analysis. A pragmatic
approach was adopted, and complications that were only reported once and/or unlikely to
require acute surgical management (e.g. lymphocyst) were excluded from the meta-analysis.
We have presented results for blood transfusions, bladder injury, ureteric injury, bowel
injury, nerve injury, vascular injury, conversion to laparotomy (for planned laparoscopic
cases), fistula, pulmonary embolism, combined thromboembolic events (pulmonary embolism
and venous thromboembolism), and infectious morbidity. Infectious morbidity included
wound infection, post-operative infection, urinary tract infection, urosepsis, vaginal cuff infec-
tion, febrile morbidity, necrotising fasciitis, pelvic cellulitis, pneumonia, pyelonephritis, and
pelvic abscess.
Cervical cancer surgery in LMIC
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Assessment of methodological and reporting quality
Methodological quality was assessed using the Cochrane Risk of Bias tool for randomized tri-
als. For non-randomised studies, the Newcastle-Ottawa Scale (NOS) was adapted and used for
the cohort studies [18]. We also included three elements (all outcome measures reported,
methods of assessment for outcome provided, authors discuss potential sources of bias) from
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) quality
assessment tool when assessing cohort studies [19–21].
Fig 1. PRISMA flowchart.
https://doi.org/10.1371/journal.pone.0217775.g001
Cervical cancer surgery in LMIC
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Meta-analysis
Studies were included in the meta-analysis if they were assessed as high quality. Randomised
control trials were excluded from the analysis if they had a high risk of bias in any domain
[22]. Cohort studies were excluded if they had a Newcastle-Ottawa score of less than 7 [23].
Statistical analysis
Summary estimates and 95% confidence intervals (CIs) for various complication types were
obtained with a random effects model by pooling proportions from each study[24]. A random
effects model for pooling proportions was used to account for variability in the effect estimates
and subgroup meta-analyses were used to distinguish the respective treatments performed (i.e.
laparotomy vs. laparoscopic surgery)[25]. The percentage of total variation across studies due
to heterogeneity was evaluated by the I2 measure[26, 27]. Forrest plots were drawn showing
the variation of the specific surgical complication rate among all studies together with the
pooled estimate measure[28, 29]. Given the large number of studies included from China, a
sensitivity analysis was conducted that excluded all Chinese studies. Funnel plots were used to
assess the potential role of publication bias. Egger’s test was used as a formal test of funnel plot
asymmetry and publication bias[30]. Stata, version 15.0 (Stata Corp., College Station, TX,
USA), was used for statistical analysis[31].
Registration
The protocol for this review was registered PROSPERO registration number CRD420170572
05.
Results
Fig 1 shows the selection of studies. A total number of 56 articles met the study inclusion crite-
ria. Two studies which reported on trachelectomy only were excluded from the meta-analysis
[32, 33]. One high quality study included stage 4 cancers (the remainder included only early
stage disease 1A-2B) and was excluded from the analysis. Figs 2 and 3 present the risk of bias
assessment in the included high quality studies. Studies were high quality in most domains;
however, it was common that stage of disease was not controlled for, and that the assessment
of the outcome and the method of assessment were not adequately described.
After excluding low-quality studies, data were available for 46 studies [34–79], for 10,847
patients (from 2 randomized trials, 9 prospective and 35 retrospective studies) from 11 mid-
dle-income countries (Fig 4). Low income country studies from Asia, Africa, South America
and Russia were excluded studies as they were assessed as low quality studies. Characteristics
of included studies are shown in Table 1. The median age of participants was in the 5th or 6th
decade in all but one study[40]. The study authors variably described surgical approaches, and
while inclusion criteria specified the need for confirmed malignancy, this was rarely confirmed
with post-operative histology. 10814 patients had a radical hysterectomy. 33 had a simple hys-
terectomy. 2,187 patients had a laparoscopic procedure, and 8,660 patients had a laparotomy.
Surgery was performed in a wide variety of centres, from general hospitals to specialised cancer
units. 23 high quality studies included 1663/4572 patients (36.4%) that had neoadjuvant treat-
ment, both chemotherapy and / or radiotherapy. The neoadjuvant treatment regimens were
varied and are not reported here.
Sixty-six separate complications in all studies (high and low quality) were reported on (the
full list is available in S1 File).
Cervical cancer surgery in LMIC
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Blood transfusion
The need for blood transfusion was reported in fifteen studies (3,108 patients) with a pooled
estimate of 29% (95% CI 0.19–0.41, P = 0.00, I2 = 97.81). Pooled estimates varied greatly
between laparotomy cases (42%, 95% CI 0.32–0.53, I2 = 95.75, P = 0.00) and laparoscopic cases
(10%, 95% CI 0.04–0.16, P = 0.00, I2 = 85.75). High heterogeneity was present for both analyses
(refer to Fig 5).
Fig 2. Risk of bias assessment in the included cohort studies.
https://doi.org/10.1371/journal.pone.0217775.g002
Fig 3. Risk of bias assessment in the included randomised studies.
https://doi.org/10.1371/journal.pone.0217775.g003
Cervical cancer surgery in LMIC
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Nerve injury
Four studies (995 patients) reported nerve injury as an intraoperative complication. The over-
all pooled estimated was 1% (95% CI 0.00–0.03, I2 77.80, P = 0.00). Pooled estimates were
higher for laparotomy cases (3%, 95% CI 0.05–0.14) than for laparoscopic cases (0.3%, 95% CI
0.00–0.10). Overall high heterogeneity was identified for both analyses (I2 77.8, P = 0.00).
Bowel injury
Six studies (1,957 patients) reported bowel injury, with a pooled estimate of 0.5% (95% CI
0.01–0.01, I2 = 0.00, P = 0.77). Pooled estimates were slightly higher for laparotomy cases
(0.7%, 95% CI 0.01–0.01) than in laparoscopic cases (0.4%, 95% CI 0.00–0.01). Low heteroge-
neity was identified for both analyses.
Bladder injury
Bladder injury was reported in sixteen studies (4,643 patients) and had a pooled estimate
of 1% (95% CI 0.01–0.02, P = 0.10, I2 = 32.2). Pooled estimates varied slightly between laparot-
omy cases 1% (95% CI 0.01–0.02, I2 = 0.00, P = 0.92) and laparoscopic cases (2%, 95% CI 0.01–
0.02, P = 0.07, I2 36.67). Low heterogeneity was identified for laparotomy and moderate het-
erogeneity for laparoscopy (refer to Fig 6).
Fig 4. Distribution of included patients in LMIC.
https://doi.org/10.1371/journal.pone.0217775.g004
Cervical cancer surgery in LMIC
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Table 1. Characteristics of included high quality studies.
Reference Country Study design Total study
cohort
FIGO stage Type of surgery� Mode(s) of surgery
Srisomboon, 2002 (24) Thailand RCT 100 1A2-2A RH and PLND Laparotomy
Cai, 2006 (25) China RCT 106 1B RH and PLND Laparotomy
Cao, 2006 [36] China Retrospective
cohort
139 1A-2B RH and PLND Laparotomy
Coruasic, 2007 [37] Croatia Cohort�� 52 1A-1B RH Laparoscopy,
laparotomy
Li, 2007 [38] China Retrospective
cohort
125 1B-2A RH and PLND Laparoscopy,
laparotomy
Likic-Ladevic, 2007 [39] Serbia Prospective cohort 536 1B-2B RH Laparotomy
Puntambekar, 2007 [40] India Retrospective
cohort
252 1A2-1B1 RH and PLND Laparoscopy
Xu, 2007 [41] China Retrospective
cohort
317 1B-2A RH and PLND +/- aortic
LND
Laparoscopy
Chen, 2008 [42] China Retrospective
cohort
295 1A2-2B RH and PLND +/- aortic
LND
Laparoscopy
Kietpeerakool, 2008 [43] Thailand Retrospective
cohort
357 1B2-2B RH and PLND Laparotomy
Likic, 2008 [44] Serbia Prospective cohort 536 1B RH Laparotomy
Liu, 2008[96] China Retrospective
cohort
143 1A-2B RH and PLND Laparotomy
Cai, 2009 [45] China Prospective cohort 480 1B-2A RH Laparotomy
Ju, 2009 [46] China Retrospective
cohort
93 1A-2B RH Laparotomy
Manchana, 2009 [47] Thailand Retrospective
cohort
281 1B-2A RH Laparotomy
Cai, 2010 [48] China Retrospective
cohort
372 1B-2A RH Laparotomy
Espino-Strebel, 2010 [49] Philippines Retrospective
cohort
79 1-2A RH Laparotomy
Zhu, 2010 [50] China Retrospective
cohort
132 IB-2A RH Laparotomy
Bezerra, 2011 [51] Brazil Retrospective
cohort
88 1A-2A RH and PLND Laparotomy
Hou, 2011 [52] China Prospective cohort 63 1A-2B RH and PLND Laparoscopy,
laparotomy
Li, 2011 [53] China Prospective cohort 73 1B2-2A RH Laparotomy
Lucic, 2011 [54] Bosnia and
Herzegovina
Retrospective
cohort
177 1B1-2B RH Laparotomy
Yan, 2011 [55] China Retrospective
cohort
240 1A2-2B RH and PLND Laparoscopy
Zheng, 2011 [56] China Retrospective
cohort
960 1B-2B RH Laparotomy
Zhou, 2011 [57] China Retrospective
cohort
80 1B2-2A RH and PLND Laparotomy
Zhu, 2011 [58] China Cohort�� 61 1B1-2A RH Laparotomy
Achavanuntakul, 2012
[59]
Thailand Retrospective
cohort
456 1A2-2A RH and PLND Laparotomy
Li, 2012 [60] China Retrospective
cohort
391 1A2-2B RH and PLND +/- aortic
LND
Laparotomy
Pareja, 2012 [61] Colombia Retrospective
cohort
47 1A2-1B2 RH Laparoscopy
Yan, 2012 [62] China Retrospective
cohort
148 1B1 RH and PLND Laparoscopy
(Continued)
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Table 1. (Continued)
Reference Country Study design Total study
cohort
FIGO stage Type of surgery� Mode(s) of surgery
Ma, 2013 [97] China Retrospective
cohort
50 1B2-2A RH and PLND Laparotomy
Mahawerawat, 2013 [63] Thailand Retrospective
cohort
58 1A2 RH and PLND Laparotomy
Chai, 2014 [64] China Retrospective
cohort
438 2B RH and PLND Laparotomy
Favero, 2014 [65] Brazil Prospective cohort 33 1B2-2B Extra-fascial hysterectomy Laparoscopy
Li, 2014 [66] China Retrospective
cohort
134 1B1-2A2 RH and PLND Laparoscopy,
laparotomy
Makowski, 2014 [67] Poland Retrospective
cohort
73 1A2-2A1 RH Laparotomy
Zhang, 2014 [68] China Prospective cohort 126 1B1 RH and PLND Laparotomy
Chen, 2015[98] China Retrospective
cohort
137 1B-2A RH Laparotomy
Durdevic, 2015 [69] Serbia Retrospective
cohort
175 1B-2B RH Laparotomy
Xie, 2015 [70] China Retrospective
cohort
86 1B1-2A1 RH Laparoscopy
Yang, 2015 [71] China Retrospective
cohort
403 1A1-2B RH and PLND Laparoscopy
Yang, 2105 [72] China Retrospective
cohort
120 1B2-2B RH and PLND + aortic LND Laparotomy
Gong, 2016 [73] China Retrospective
cohort
800 1B2-2B RH Laparotomy
Liu, 2016 [74] China Prospective cohort 120 1B2-2A2 RH Laparoscopy
Wu, 2016 [75] China Retrospective
cohort
839 1B1-2A2 RH Laparotomy
Yang, 2016 [76] China Prospective cohort 76 1B1-2A2 RH Laparoscopy
� RH = radical hysterectomy, PLND = pelvic lymph node dissection, LND = lymph node dissection
�� Not reported as retrospective or prospective
https://doi.org/10.1371/journal.pone.0217775.t001
Fig 5. Annotated Forrest plot of overall prevalence of blood transfusion (A) and prevalence by surgical mode (B).
https://doi.org/10.1371/journal.pone.0217775.g005
Cervical cancer surgery in LMIC
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Ureteric injury
Fourteen studies (3,063 patients) reported ureteric injury, with a pooled estimate of 1% (95%
CI 0.01–0.01, I2 0.00, P = 0.64). Pooled estimates were equivalent for laparotomy cases 1%
(95% CI 0.01–0.01, I2 0.00, P = 0.53) and laparoscopic cases (1%, 95% CI 0.00–0.01, I2 0.00,
P = 0.78). The included studies had low heterogeneity in both analyses (refer to Fig 7).
Vascular injury
Fourteen studies reported vascular injury (2,758 patients) and had a pooled estimate of 2% (95%
CI 0.01–0.03, I2 60.22, P = 0.00). Pooled estimates were lower for laparotomy cases 1% (95% CI
0.01–0.04, I2 57.24, P = 0.03) than for laparoscopic cases 2% (95% CI 0.01–0.04, I2 42.10, P = 0.10).
Overall high heterogeneity was identified for both analyses (I2 58.06, P = 0.00) (refer to Fig 8).
Fig 6. Annotated Forrest plot of overall prevalence of bladder injury (A) and prevalence by surgical mode (B).
https://doi.org/10.1371/journal.pone.0217775.g006
Fig 7. Annotated Forrest plot of overall prevalence of ureteric injury (A) and prevalence by surgical mode (B).
https://doi.org/10.1371/journal.pone.0217775.g007
Cervical cancer surgery in LMIC
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Fistula
Fourteen studies (4,429 patients) reported fistula as a surgical complication. Fistula was defined
by the study authors and not necessarily definitive as to type (e.g. vesicovaginal or rectovaginal).
The overall pooled estimated was 2% (95% CI 0.01–0.03, I2 = 77.32, P = 0.00,). Pooled estimates
were comparable between laparotomy cases (2%, 95% CI 0.01–0.04, P = 0.00, I2 = 86.19) and
laparoscopic cases (1%, 95% CI 0.01–0.01, I2 = 22.70, P = 0.26). Overall high heterogeneity was
identified for laparotomy and moderate heterogeneity for laparoscopy (refer to Fig 9).
Fig 8. Annotated Forrest plot of overall prevalence of vascular injury (A) and prevalence by surgical mode (B).
https://doi.org/10.1371/journal.pone.0217775.g008
Fig 9. Annotated Forrest plot of overall prevalence of fistula injury (A) and prevalence by surgical mode (B).
https://doi.org/10.1371/journal.pone.0217775.g009
Cervical cancer surgery in LMIC
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Conversion to open surgery
There were three studies (1015 patients) that reported the requirement to convert to open sur-
gery. The overall pooled estimate was 1% (95% CI 0.00–0.02, I2 = 21.29, P = 0.28) and the
included studies showed moderate heterogeneity.
Thromboembolic events
Pulmonary embolism was reported in five studies (that included 1,270 patients) as a postoper-
ative complication. The pooled estimate was 0.4% (95% CI 0.00–0.01, I2 26.69, P = 0.25). Seven
studies reported on all thromboembolic events (that included 1,501 patients) and had a pooled
estimate of 1% (95% CI 0.01–0.02, I2 0.00, P = 0.73). Pooled estimates were comparable for RH
(laparotomy) cases (1%, 95% CI 0.00–0.02) vs. RH (laparoscopic) cases (1%, 95% CI 0.00–
0.05). Overall the included studies showed low heterogeneity for both analyses (I2 0.00,
P = 0.73).
Infectious morbidity
There were twenty studies (3,826 patients) that reported infectious morbidity as a postopera-
tive complication. The overall pooled estimated was 8% (95% CI 0.04–0.12, I2 95.72, P = 0.00).
Pooled estimates were higher for RH (laparotomy) cases 9% (95% CI 0.05–0.14, I2 = 95.82,
P = 0.00) vs. RH (laparoscopic) cases 5% (95% CI 0.00–0.12, I2 88.88, P = 0.00). High heteroge-
neity was identified for both analyses (refer to Fig 10).
Assessment of complications excluding studies from China
For the complications of blood transfusion, bladder injury, ureteric injury, vascular injury and
fistula, there was less than 0.08 difference in the random pooled estimates when studies from
China were excluded. (S2 Table).
Progression free survival (PFS) and overall survival (OS)
The 5-year PFS was reported for 4,731 patients from 17 studies. Overall PFS was 81.15%, 83%
for laparotomy (n = 3,917; 95% CI:0.75–0.89) and 84% for laparoscopy (n = 664; 95% CI:0.81–
0.87). The 5-year OS was reported for 5130 patients from 16 studies. OS was 83.5%, 85% for
laparotomy cases (n = 4,466; 95% CI: 0.78–0.91) and 80% for laparoscopy (n = 664; 95%
CI:0.72–0.88).
Assessment of publication bias
There was no apparent publication bias for all complications included in the meta-analysis.
Funnel plots and p values of Egger’s test for each complication are shown in S2 File
Discussion
To our knowledge, this is the first systematic review and meta-analysis of morbidity after pri-
mary surgical management of cervical cancer specifically in LMIC, although only data from
middle-income countries (MIC) were included in the meta-analysis. The incidence of compli-
cations in this meta-analysis is largely comparable to those reported in high-income countries
(HIC). Blood transfusions are reported in HIC at up to 25% for minimally invasive surgical
approaches for cervical cancer and up to 75% for laparotomy[80], and so our findings of 10%
and 42% respectively are consistent with published studies that have been conducted in well
resourced settings. This may however also reflect differing resources and thresholds for
Cervical cancer surgery in LMIC
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Fig 10. Annotated Forrest plot of overall prevalence of infection (A) and prevalence by surgical mode (B).
https://doi.org/10.1371/journal.pone.0217775.g010
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transfusions in LMIC. In HIC 1.2% and 2.8% of women develop fistula (ureterovaginal and
vesicovaginal) and pulmonary embolism respectively[81] following surgery for cervical cancer.
Ureteric injuries following laparotomy and radical hysterectomy for cervical cancer were
reported to occur in 2.48% of cases in a review of nearly 400,000 hysterectomies in the United
Kingdom (UK)[82]. The reported incidence of complications is similar or lower in this meta-
analysis and may represent publication bias. However, our findings suggest that, morbidity fol-
lowing surgery for cervical cancer in MIC appears to compare favourably to the reported inci-
dence in HIC.
The comparative survival between laparoscopy and laparotomy cases in this review is
clearly different to that of a recently published retrospective cohort study [83] and prospective
RCT in HIC [84]. However, our data is neither registry based nor largely prospective so com-
parisons should be made with caution. It is reassuring that the risks of complications reported
in this meta-analysis are comparable to HICs. Accepting that some settings within LMIC have
individual survival rates more comparable to HIC[85], overall long-term outcomes do not
compare favourably for cervical cancer patients in LMIC where overall 5-year survival rate is
50%, which is markedly different to HIC, which report survival rates up to 80%. Reasons for
this difference may include the stages of tumour (e.g. 2B), being offered operative care which
may not happen in HIC, high rates of HIV positivity in these settings in women who are youn-
ger at diagnosis than non-HIV positive women, although in many settings their outcomes
appear comparable[86]. Equally, surgeons are frequently the mainstay of treatment for women
in LMIC and the lack of adjuvant treatment likely impacts on outcomes[3, 6].
The strengths of the current study include the rigorous inclusion criteria and a search that
was not limited by language. Moreover, the broad search criteria were not limited to LMIC
(which are not necessarily linked in MeSH terms or titles and abstracts) and so this increased
the likelihood of capturing studies reporting on outcomes in LMIC. A large number of both
articles and patients were included in the meta-analysis with a surgical treatment period since
2000, which is likely reflective of current practice. Each complication has a large denominator,
although we accept that the definition of morbidity (in both high income and LMIC studies) is
not necessarily standardised, and subject to variations in regional practices and definitions
[87]. However, we have only included high quality studies in the meta-analysis, adding to its
robustness.
There are several limitations to this study. As the main body of data are derived from retro-
spective studies with high heterogeneity, a random-effects model was applied to decrease the
possibility of overestimating surgical morbidity. Nevertheless, the retrospective and unblinded
study designs of the majority of included studies may introduce biases that cannot be evalu-
ated. Furthermore, there is variability in surgical approaches, including lymphadenectomy,
that potentially affect the meta-analysis; however this is reflective of current surgical practice,
and the issue is similar to that encountered in other meta-analyses of surgical complications
[88].
Operative morbidity could also be influenced by neoadjuvant chemotherapy. A recent ran-
domized trial from India reported inferior disease-free survival (DFS) with neoadjuvant-che-
motherapy followed by surgery compared to concurrent chemoradiation. This study has also
reported operative morbidity. Patients randomised to neoadjuvant chemotherapy had a signif-
icantly higher rate of grade 3 or 4 thrombocytopenia compared to those treated by concurrent
chemoradiation, but there was no significant difference between the two groups in grade 3 or
4 gastrointestinal and bladder toxicities. In the neoadjuvant chemotherapy plus surgery group,
perioperative hemorrhage with 1000 mL blood loss occurred in 7.9% of patients[89]. In view
of the superior DFS with chemoradiation it is conceivable that the neoadjuvant modality
might decline in the future. Due to the heterogeneity of the regimens of the included studies, it
Cervical cancer surgery in LMIC
PLOS ONE | https://doi.org/10.1371/journal.pone.0217775 July 3, 2019 14 / 21
was not possible to analyse the impact of neoadjuvant and adjuvant therapies on surgical mor-
bidity in this meta-analysis.
Only one high quality study[65] reported on simple hysterectomy rather than radical hyster-
ectomy. However, this study included only 33 patients and so is unlikely to impact on the out-
come of the meta-analyses. Equally patient co-morbidities that confound complication results
are not reported. No high-quality studies from LICs were included and there is little representa-
tion from Africa in this analysis (2 studies from this region that met inclusion criteria were
excluded at the quality assessment stage) and furthermore, data from China represents 65% of
the included studies. This may account for the reported incidences of surgical complications in
the current meta-analysis, which are comparable to those in high-income countries, as many
parts of China are increasingly becoming higher income settings[90]. However, the similar
pooled estimates for reported complications in our sensitivity analysis that excluded studies
from China do not support this. It is also plausible that the surgical case load and experience in
caring for cervical cancer cases in LMIC mitigates the limitations in these settings and results in
comparable surgical complications with HIC. An important limitation is that included data
were not population or registry based. This may explain the relatively high progression free and
overall survival reported in our study, which is markedly different to that reported by Allemani
and colleagues, with 5 year OS in LMIC of around 50% [91], based on population registry data
that included patients with all stages of cervical cancer. Finally, it was not possible to stratify sur-
gical complications by stage of disease or timing of the complication (e.g. immediately post-
operative or delayed complication) as this was infrequently reported in the included studies.
Given these limitations, there is a clear lack of globally comprehensive and representative
data on surgical outcomes in LMIC[8, 92], which, by virtue of inadequate assessment of defi-
ciencies where resources can be targeted, and by limiting knowledge on the natural history
and variations in cancer outcomes in these settings, worsens cancer care[3]. Data are particu-
larly lacking from LICs. Developing registries to meet this gap is critical in addressing the
global burden of non-communicable diseases including cancer[93], particularly with increas-
ing access to adjuvant therapies in these settings. Inclusive access to the most basic cervical
cancer management is lacking in LMIC and system strengthening is critical to changing this
[94]. The Lancet Commission on Global Surgery clearly outlines that scale-up of universal
access to safe surgical care includes the need for strong system development grounded in data
collection, including surgical indicators, such that system issues and deficiencies can be identi-
fied and changes advocated for. If we are to meet these goals then, similar to global efforts to
count every newborn[95], the oncology community urgently needs to work with LMIC policy
makers to ensure longitudinal data collection and the counting of every cancer case[91, 92].
Conclusion
This is the first systematic review and meta-analysis of surgical morbidity in cervical cancer in
LMIC and provides a benchmark for future health services research and policy implementa-
tion. Surgery is the cornerstone of management in early stage cervical cancer and is likely to
remain a major treatment modality in LMIC for many years; we must as a global oncology
community mobilise to ensure the foundations for health advocacy and program development
are in place, including surgical morbidity registries.
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